Alzheimer’s Drug Candidate Showed Favorable Safety Profile
A new Phase 1 study of trabzanoflast suggests the drug is well-tolerated by healthy volunteers.
Updated on Sept. 30, 2026 in Alzheimer’s
Live Poll
Do you generally trust pharmaceutical companies to successfully develop safe and effective new brain-targeting medications?
Rezera has released early-stage clinical trial results for its investigational neuroinflammatory treatment, trabzanoflast. The study confirms that the drug was well-tolerated in the 55 healthy adult volunteers who participated.
Why it matters
This development marks a step forward in creating treatments designed to reach the central nervous system effectively. By demonstrating target engagement, the trial provides foundational data for future research into neuroinflammatory conditions.
In a Phase 1 randomized trial of 55 healthy adults, trabzanoflast showed dose-proportional exposure and confirmed target engagement. No serious adverse events or discontinuations were reported in this preliminary safety assessment.
The players
Rezera
A biopharmaceutical company focused on developing therapies for neuroinflammatory diseases.
The details
Trabzanoflast is designed to achieve high penetration within the central nervous system to address neuroinflammatory disease pathways. The trial utilized single and multiple ascending dose cohorts to evaluate safety, achieving a Kp,uu value of 1.9 in cerebrospinal fluid. Based on these findings, brain exposure levels are expected to remain above the IC90 threshold at trough.
Timeline
September 30, 2026: Rezera announced the Phase 1 clinical trial results.
Health Landscape
This drug candidate fits into the ongoing search for therapeutics that can effectively cross the blood-brain barrier to treat neurodegenerative conditions. The study extends existing efforts to optimize CNS-penetrant drug delivery in the development of treatments for neuroinflammatory disorders.
These findings are strictly preliminary and limited to healthy volunteers, meaning they do not yet indicate a treatment option for current patients. Any questions about the status of emerging Alzheimer’s or neuroinflammatory research are best discussed with a neurologist.
The takeaway
Early-stage safety data suggests that trabzanoflast can penetrate the central nervous system as intended without causing serious side effects. Readers should continue to follow the clinical progress of new neuro-therapies through updates from the drug developer.
Further reading
For broader context on how research into neuroinflammation is evolving, visit our Alzheimer’s section.
Live Poll
Do you generally trust pharmaceutical companies to successfully develop safe and effective new brain-targeting medications?
